Surface cooling for induction of mild hypothermia in conscious healthy volunteers - a feasibility trial by Testori, Christoph et al.
RESEARCH Open Access
Surface cooling for induction of mild
hypothermia in conscious healthy volunteers -
a feasibility trial
Christoph Testori
1, Fritz Sterz
1*, Wilhelm Behringer
1, Alexander Spiel
1, Christa Firbas
2 and Bernd Jilma
2
Abstract
Introduction: Animal and human studies suggest beneficial outcome effects of mild hypothermia for stroke, for
acute myocardial infarction, and for cardiogenic shock. The aim of this study was to investigate the feasibility and
safety of non-invasive surface cooling for induction and maintenance of mild hypothermia (32 to 34°C) in healthy,
conscious volunteers.
Methods: The trial was set at a clinical research ward in a tertiary care center, and included 16 healthy male
volunteers 18 to 70 years old. Surface cooling was established by a novel non-invasive cooling pad with an
esophageal target temperature of 32 to 34°C and maintenance for six hours. Shivering-control was achieved with
meperidine and buspirone and additional administration of magnesium in eight subjects.
Results: The primary endpoint to reach a target temperature of 32 to 34°C was only reached in 6 of the 16
participating subjects. Temperatures below 35°C were reached after a median cooling time of 53 minutes (38 to
102 minutes). Cooling rate was 1.1°C/h (0.7 to 1.8°C). Additional administration of magnesium had no influence on
cooling rate. At no time during the cooling procedure did the participants report uncomfortable conditions for
which termination of cooling had to be considered. No severe skin damage was reported.
Conclusions: Cooling to body temperature below 35°C by the use of non-invasive surface cooling is feasible and
safe in conscious healthy volunteers. Further studies are needed to investigate an altered cooling protocol to
achieve temperatures below 35°C.
Trial Registration: ISRCTN: ISRCTN50530495
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Introduction
Therapeutic hypothermia improves neurological out-
come and reduces the risk of death in patients after car-
diac arrest [1,2]. In recent years, growing evidence in
animal and human studies have documented or sug-
gested the beneficial outcome effects of mild hypother-
mia also for stroke [3-11], for acute myocardial
infarction [12-16], and for cardiogenic shock [17].
Rather than interacting on a particular pathway of post-
ischemic reperfusion damage hypothermia influences
multiple reactions leading to cell death [18-20].
So far, the majority of therapeutic hypothermia
research has involved cardiac arrest patients, in whom
the induction and maintenance of mild hypothermia is
facilitated by post-anoxic coma, anesthesia and paralysis
to avoid shivering. The typical patient presenting to an
emergency department with ischemic stroke or acute
myocardial infarction is awake and does not present in a
clinical status that necessitates intubation and neuro-
muscular blockade. The induction of mild hypothermia
in these patients remains a challenge. Recent studies
investigated various methods for inducing mild
hypothermia in awake volunteers or awake patients,
such as infusion of cold saline [21,22], surface cooling
with circulating chilled water through energy transfer
pads placed on the patients’ skin [14,23,24], or
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infusion of cold saline does not provide sustained mild
hypothermia [29], and cooling devices are bulky and
need an electrical power supply, thus preventing the use
of these devices in the out-of-hospital setting. Endovas-
cular cooling necessitates the puncture of a main venous
blood vessel with all its complications, such as arterial
puncture, hematoma, pneumothorax, venous thrombosis
and catheter-related infections [30-33]. Recently, a sim-
ple to use, non invasive cooling pad, independent of an
energy source during use, was developed, which proved
to rapidly induce mild hypothermia in patients after car-
diac arrest in the out-of-hospital setting [34] and in the
emergency department [35].
The aim of this study was to investigate the feasibility
and safety of non-invasive surface cooling for induction
and maintenance of mild hypothermia (32 to 34°C) in
healthy, conscious volunteers.
Materials and methods
Study design
This study was conducted according to the principles of
the Declaration of Helsinki (Version 4, 2004) and was
approved by the Ethics Committee of the Medical Uni-
versity of Vienna. This was a prospective interventional
study in a cohort of 16 healthy volunteers. Subjects
were informed verbally and in writing about the aims of
the study. Each volunteer provided written informed
consent. Financial compensation was according to stan-
dard operating procedures of the Department for Clini-
cal Pharmacology, Medical University of Vienna.
Study setting and population
Volunteers 18 to 70 years old were included. We
excluded pregnant women, subjects with a known pre-
existing cardiopulmonary disease or pre-existing malig-
nancy, those with pre-existing coagulopathy, with an
active dermatologic condition, with a current treatment
with monoamine oxidase inhibitors, with previous or
current drug abuse, and with a known allergy to the
study medication. Core temperature had to be below 37°
C at the start of the cooling procedure.
Study protocol
Prior to enrolment, a general health check was per-
formed for each subject. This examination included a
general physical examination, lab tests, resting ECG and
chest X-ray. Abstinence from alcohol, tobacco and
strenuous exercise for 12 hours before the study were
requested. Subjects were asked to only consume a light
meal before their study day at the research ward to
minimize any potential nausea caused by meperidine
infusion. Compliance with these requests was confirmed
by interview before each trial. Before initiation of
cooling, volunteers were asked about any symptoms of
infection to avoid aggravation of an incipient disease.
Medication: After baseline measurements, meperidine
(Alodan
®,G e r o t ,V i e n n a ,A u s t r i a )1m g / k gb o l u s ,f o l -
lowed by 30 mg/h intravenously, and on oral dose of
buspirone (Buspar
®, Bristol-Myers Squibb, Meymac,
France) 30 mg was given to prevent shivering. A single
bolus of granisetron hydrochloride (Kytril
®,R o c h eA u s -
tria, Vienna, Austria) 3 mg was administered intrave-
nously to prevent nausea. A continuous fluid drip with
an isotonic electrolyte solution (Elomel iso
®,F r e s e n i u s
Kabi Austria, Graz, Austria) with an infusion rate of 100
ml/h was administered throughout the cooling period.
Because of problems reaching the target temperature of
32 to 34°C we decided to additionally administer a bolus
of 4 g magnesium sulfate (MgSO4) over 30 minutes fol-
lowed by a continuous intravenous drip of 2 g/h for 150
minutes. As such, the administration of magnesium was
limited to eight volunteers.
Cooling procedure: The cooling pads (EMCOOLSpad
®,
Emcools AG, Pfaffstaetten, Austria), each 20 × 30 cm,
consist of multiple cooling cells filled with a patented
cooling gel. The inner layer is a biocompatible film that
adheres to the patient’s skin on application and provides
intimate pad to skin contact for efficient heat transfer.
The cooling units were stored in a cooling box at -2°C
before use. Six cooling units were applied on the back,
thorax, abdomen and thighs of the volunteers. In pre-
vious studies in patients after cardiac arrest, a tempera-
ture drop was observed after the removal of the cooling
units [34,35]; thus, in this study, the cooling units were
removed when a core temperature of 35°C was reached.
Target core temperature was 32 to 34°C and maintained
for six hours. The following algorithm was applied to
maintain the temperature: if the temperature did not
drop below 34.3°C, or the temperature started to
increase before reaching 34.3°C, two cooling units were
applied on the thorax and abdomen, until the tempera-
ture reached 34°C, then the cooling units were removed
(cooling units were exchanged when thawed). If the
temperature dropped below 33°C, a warming blanket
was applied until the temperature reached 33.1°C.
After six hours, the volunteers were covered with a
blanket and allowed to re-warm. At a temperature of
35°C, meperidine was stopped, and the volunteers were
observed for additional 16 hours.
Measures
Core temperature was measured continuously with a
temperature probe (Mon-a-therm
® 9Fr/Ch; Tyco
Healthcare, Mansfield, MA, USA) advanced into the
esophagus, and recorded continuously. The esophageal
probe was inserted through the nose. To avoid discom-
fort and vomiting, local anesthesia with lidocain spray
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®,A s t r a Z e n e c aG m b H ,W e d e l ,G e r -
many) was applied. Blood pressure was measured non-
invasively with Riva-Rocci (Philips Healthcare; Andover,
MA, USA), and recorded every 15 minutes. ECG, heart
rate and peripheral oxygen saturation were recorded
continuously. An intravenous line was placed into a per-
ipheral vein for administration of medication and for
blood sampling. A comfort score was recorded every 10
minutes during initial cooling, and every 30 minutes
during maintenance cooling. The comfort was measured
by a 5-point scale: 1 = extremely uncomfortable,
immediate withdrawal; 2 = very uncomfortable, withdra-
wal imminent; 3 = unpleasant, no reason for withdrawal
at this time; 4 = no specific sensations, continue the
observation; 5 = pleasant sensation, continue the obser-
vation. Volunteers were monitored for shivering using a
4-point scale [36]: 0 = no shivering evident; 1 = isolated
facial or masticatory fasciculation; 2 = peripheral shiver-
ing; 3 = uncontrolled rigor. In case of shivering or a
comfort score of ≤ 3, a meperidine 20 mg bolus, fol-
lowed by an increase of the meperidine drip rate by 5
mg/h, was given. At the end of the observational period,
the skin of all subjects was examined by a dermatologist
using a 5-point scale (severe - frost bite; moderate - skin
trauma; medium - red skin; mild - pink skin; no visible
skin irritation). Due to feasibility and the convenience of
the volunteers, the period of active cooling was set at
six hours.
Data analysis
Continuous variables are given as mean ± standard
deviation, or as median and the minimum/maximum
range, if not normally distributed. Nominal data are
given as counts and percentage of total number. For
group comparisons of continuous variables the Student’s
t-test, or the Mann-Whitney-U-test were used. For
group comparisons of proportions, the Chi Square test
or Fishers Exact test were used. For comparisons within
a group, the paired t-test or Wilcoxon Signed Rank test
were used. Cooling rates were calculated by the time
needed from baseline temperature to an esophageal
temperature of 35.0°C. SPSS software (version 16.0,
SPSS Inc., Chicago, IL, USA) and Microsoft Excel (ver-
sion 12.0 for Mac, Microsoft Corp., Redmond, WA,
USA) were used for statistical analysis.
Results
All 16 healthy male volunteers aged between 21 and 47
years followed the protocol. Median age was 32 years
(21 to 47 years), and median body mass index was 23.3
kg/m
2 (19.5 to 29.1 kg/m
2); four volunteers were
smokers.
In 11 volunteers, all cooling units had to be exchanged
before reaching an esophageal temperature of 35°C,
b e c a u s et h e yw e r ec o m p l e t e l yt h a w e d .E s o p h a g e a lt e m -
perature decreased from baseline median 36.2°C (35.7 to
36.8°C) to 35°C within a median time of 53 minutes (38
to 102 minutes), which translates into a median cooling
rate of 1.1°C/h (0.7 to 1.8°C/h). We found no correlation
between body mass index and cooling rate (P = 0.62).
Only in one volunteer, core temperature dropped below
34°C after removal of the six initial cooling units. All
volunteers started to rewarm after initial cooling so that
two maintenance-cooling units had to be applied and
h a dt ob er e p l a c e df o u rt i m e s( t w ot of i v et i m e s )
b e c a u s et h e yw e r ec o m p l e t e l yt h a w e d .E s o p h a g e a lt e m -
perature could be decreased to a minimum temperature
of 34.4°C (33.7 to 34.7°C) during the cooling procedure.
An esophageal temperature below 34°C could be estab-
lished in six subjects. After six hours of cooling, esopha-
geal temperature was 34.7°C (34.0 to 35.8°C). (Figure 1)
There was no statistically significant difference in the
time to achieve 35°C between those volunteers receiving
MgSO4 and those not receiving MgSO4 (48 minutes (38
to 93 minutes) vs. 67 minutes (44 to 102 minutes); P =
0.13)). Minimal temperature reached was significantly
lower in volunteers receiving MgSO4 (34.2°C (33.7 to
34.4°C) vs. 34.4°C (33.9 to 34.7°C); P = 0.03)). Tempera-
tures at the end of the cooling period were lower in
subjects receiving MgSO4 (34.5°C (34.0 to 35.3°C)) as
compared to those not receiving MgSO4 (34.8°C (34.3 to
35.8°C)), although this was not statistically significant (P
= 0.09). Serum magnesium levels significantly increased
after infusion of the bolus from median 0.87 mmol/l
(0.82 to 0.97 mmol/l) to 1.38 mmol/l (1.12 to 1.51
mmol/l; P < 0.01). Plasma concentrations further
increased to a level of 1.54 mmol/l (1.38 to 1.59 mmol/
l) at the end of infusion time of 150 minutes and a
cumulative dosage of 9 g MgSO4. Magnesium concen-
trations prior to discharge (0.90 mmol/l; 0.85 to 0.98
mmol/l) were not significantly different from baseline (P
= 0.45).
Heart rate, respiratory rate, oxygen saturation and sys-
tolic and diastolic blood pressure decreased significantly
during cooling (Table 1), but none of the volunteers
complained about dizziness or any other signs of hemo-
dynamic impairment. There were no significant differ-
ences in the vital signs during the cooling period
between volunteers receiving MgSO4 and volunteers not
receiving MgSO4, except systolic blood pressure, which
was significantly lower in volunteers receiving MgSO4
(113 mmHg (96 to 121 mmHg) vs. 122 mmHg (114 to
133 mmHg); P = 0.015)).
During the procedure participants never reported
uncomfortable conditions necessitating termination of
cooling. There was no difference in comfort scale
between groups receiving MgSO4 or not. Shivering was
observed in four volunteers (two receiving MgSO4),
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Page 3 of 7which could be easily controlled by the adjustment of
meperidine drip. Cumulative meperidine dose was 5.8
mg/kg (4.1 to 11.5 mg/kg) with no difference in patients
additionally receiving MgSO4 and those not receiving
MgSO4 (P = 0.75).
When removing the cooling pads after initial cooling
to a core temperature of 35°C, red skin was observed in
all 16 subjects. After re-warming to temperatures > 36°
C, the skin irritation was no longer evident in two sub-
jects, changed to mild skin irritations (pink skin) in 13
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Figure 1 Temperature curves of all subjects. Upper figure: subjects not receiving MgSO4; lower figure: subjects receiving MgSO4.
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Page 4 of 7subjects, and remained as red skin in one subject. Prior
to dismissal from the study lab, 10 volunteers still had
pink skin. All subjects were followed up for seven days.
Skin irritation decreased in all subjects during the fol-
low-up period.
Discussion
This trial showed that cooling by a novel non-invasive
surface cooling pad to temperatures < 35°C is feasible
and safe in healthy volunteers. Although the primary
endpoint to reach a target temperature of 32 to 34°C
was only reached in 6 of the 16 participating subjects.
With the presented study protocol we were not able to
achieve predefined ranges of mild hypothermia of 32 to
34°C.
Most of these patients with acute stroke or acute
myocardial infarction are awake and do not present in a
clinical status that necessitates intubation and neuro-
muscular blockade. Furthermore, patients with an acute
stroke require serial neurological assessments making
deep sedation or anesthesia a contraindication. Meperi-
dine and buspirone were chosen because of their pre-
viously described effects on thermoregulation in human
beings. The efficacy and use of meperidine and buspir-
one to suppress shivering have been well described in
the anesthesia literature and previous cooling studies
[21]. MgSO4 did not markedly improve the cooling rate
or comfort of subjects in our study, but might aid to
achieve and maintain lower temperatures for a longer
time period. In contrast to our results, Zweifler et al.
showed that the additional administration of MgSO4
improved the comfort in surface cooling of mildly
sedated spontaneously breathing subjects [37]. Zweifler
used a bolus infusion of 4 to 6 g MgSO4,f o l l o w e db ya
continuous drip of 1 to 3 g per hour. Taking into
account that Zweifer et al. administered MgSO4 over six
hours, the cumulative MgSO4 dose was higher in their
study. The infusion rate during the first 180 minutes
was similar to ours, and so their conclusion is not sup-
ported by our data. In our study, a bolus infusion of 4 g
MgSO4, followed by a continuous-drip of 2 g per hour
for 150 minutes significantly reduced systolic blood
pressure in our subjects. This finding might be impor-
tant for future treatment with hypothermia in patients
with myocardial infarction and cardiogenic shock, or
patients with stroke and hypotension, in whom a further
drop in blood pressure will be detrimental.
In a former study in cardiac arrest patients with the
same cooling method, cooling was more effective in
terms of cooling rate and lowest temperature achieved.
[34] This might be explained by the use of only six pads
for initial cooling in our study as compared to 10 cool-
ing units used in cardiac arrest patients [34]. In the cur-
rent study, pads were stored at approximately -2°C as
compared with a storage temperature of -9°C in cardiac
arrest patients [34]. In addition, awake subjects might
have a more evident counter-regulatory response against
cooling efforts, as compared with sedated and paralyzed
patients after cardiac arrest.
T h ei n f u s i o no fc o l ds a l i n ep r o v e dt ob eas i m p l e
method to induce mild therapeutic hypothermia in car-
diac arrest patients, but needs an additional cooling
method to maintain mild hypothermia [15,38,39]. How-
ever, in awake subjects, cold saline alone might be inef-
fective to induce mild hypothermia [22]. In addition, the
volume load of 30 mL/kg to induce mild hypothermia
might be harmful in patients with myocardial infarction
and left ventricular dysfunction.
Our study has several limitations worth mentioning.
The trial was conducted as a feasibility trial in healthy
volunteers and may or may not be extrapolated to
patients with acute stroke or acute myocardial infarc-
tion. Thermoregulation might be different in elderly or
sick patients. The major limitation of the study is the
fact that the target temperature of 32 to 34°C was not
achieved in two-thirds of the subjects. This might be
due to the removal of the cooling pads at 35°C, based
on our expectation of a more evident drop in tempera-
ture after removal of the cooling units as described in
cardiac arrest patients [34]. As a consequence, mainte-
nance cooling in the predefined ranges was not
achieved. However, in a preliminary study in patients
with myocardial infarction, lowering the core tempera-
ture to levels of only 35°C showed a significant reduc-
tion of infarct size. Animal models suggest a more
distinctive effect of hypothermia in myocardial infarction
if temperature management is initiated early in the pre-
reperfusion period [40]. Recently, Götberg et al.s t a t e d
that in myocardial infarction, hypothermia should be
initiated as soon as possible without delaying reperfu-
sion [41]. Given that this cooling method can be
initiated by paramedics in the field, and a core
Table 1 Vital signs
Baseline Cooling
a P-value
Heart rate, minute
-1 70 49 < 0.01
MMR
b 55 to 96 43 to 101
Peripheral oxygen saturation, % 98 95 < 0.01
MMR
b 93 to 100 90 to 98
Respiratory rate, minute-1 16 10 < 0.01
MMR
b 10 to 21 7 to 13
Systolic blood pressure, mmHg 134 117 < 0.01
MMR
b 113 to 149 96 to 133
Diastolic blood pressure, mmHg 68 58 < 0.01
MMR
b 54 to 94 37 to 67
alowest value during cooling procedure
bMinimum-maximum range
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Page 5 of 7temperature of 35°C was reached within 53 minutes in
the current study, patients with myocardial infarction
might be cooled to therapeutic levels of hypothermia
already during transport to the hospital.
Conclusions
Cooling to a body temperature below 35°C by the use of
non-invasive surface cooling is feasible and safe in con-
scious, healthy, mildly sedated volunteers. Further stu-
dies are needed to investigate: 1) an altered cooling
protocol to achieve temperatures below 35°C, and 2) the
feasibility and safety of surface cooling with these pads
in awake patients with stroke or acute myocardial
infarction.
Key messages
￿ Surface cooling in healthy, mildly sedated volun-
teers is feasable and safe.
￿ An altered cooling protocol is required to achieve
lower temperatures. The additional administration of
magnesium does not lead to faster cooling rates.
Abbreviations
MgSO4: magnesium sulfate
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